Hexarelin is a synthetic hexapeptide growth hormone secretagogue (GHS) and a potent agonist at the ghrelin receptor (GHS-R1a). It was developed in the early 1990s and has been studied for both its growth hormone-releasing properties and, more distinctively, its direct cardiovascular effects through mechanisms independent of GH release.
GHS-R1a Agonism and GH Release
Hexarelin is among the most potent GHS peptides tested in research models, producing substantial GH release at relatively low doses. It exhibits partial resistance to tachyphylaxis compared to some other GHS peptides, meaning it maintains effectiveness across repeated administrations better than compounds that show more rapid receptor desensitization. This characteristic has made it useful in research designs requiring repeated stimulation protocols.
Cardiovascular Research
A distinctive feature of hexarelin research is the consistent documentation of cardioprotective effects independent of GH secretion. Hexarelin binds to CD36 receptors on cardiac tissue, a receptor that does not respond to other GHS peptides. This binding is associated with improved cardiac contractility, reduced ischemia-reperfusion injury in animal models, and protection against cardiomyocyte apoptosis. Importantly, these effects persist in hypophysectomized (pituitary-removed) animals, confirming they are GH-independent.
Cardiac Ischemia Models
In standardized cardiac ischemia-reperfusion models, hexarelin treatment has consistently reduced infarct size and improved left ventricular function compared to controls. The cardioprotective signal is one of the more robust findings in the GHS peptide literature and has driven interest in hexarelin as a research tool for cardiovascular biology independent of its GH effects.
Comparison with Ipamorelin
Both hexarelin and ipamorelin are GHS-R1a agonists but differ in selectivity. Ipamorelin is highly selective for GHS-R1a and produces minimal off-target hormone release. Hexarelin, while more potent for GH release, also stimulates cortisol and ACTH at higher doses. Researchers selecting between them typically choose ipamorelin when GH selectivity is the priority and hexarelin when the cardiovascular effects are relevant to the research design.
For in vitro research use only. Not for human or veterinary use, therapeutic, or diagnostic purposes.